TLR9 and neoplasm: Overall, these data further support the notion that CPG-1668-mediated TLR9 stimulation in immune cells limits RM1 tumor growth via the secretion of type I IFN, leading to reduced RM1 cell proliferation and that RM1 cells fail to directly respond to CPG-1668.